Skip to content
Agree.net – Lifestyle
Author:
OncoC4
OncoC4 Reports Encouraging Phase 1/2 Data for Cesalatamig Monotherapy in Previously Treated Non-Small Cell Lung Cancer at SITC 2026
November 6, 2026
OncoC4 Appoints Dr. Dan Janiak as Chief Business Officer
November 2, 2026
OncoC4 Announces Oral Presentation of a Late-Breaking Abstract on Cesalatamig at the 41st Annual Meeting of SITC
October 29, 2026
OncoC4 Announces NMPA Acceptance of Two IND Applications for Cesalatamig Combination Studies with ADCs and Pan-RAS Inhibitors
October 19, 2026
OncoC4 Receives FDA Fast Track Designation for Cesalatamig, an Investigational PD-1/VEGF Bispecific Antibody
September 16, 2026
OncoC4 Appoints Dr. Steve Chen, JD, PhD as General Counsel
September 1, 2026